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Despite the effectiveness of anterior thalamic nucleus (AN) deep brain stimulation (DBS)
for the treatment of epilepsy, mechanisms responsible for the antiepileptic effects of
this therapy remain elusive. As adenosine modulates neuronal excitability and seizure
activity in animal models, we hypothesized that this nucleoside could be one of the
substrates involved in the effects of AN DBS. We applied 5 days of stimulation to
rats rendered chronically epileptic by pilocarpine injections and recorded epileptiform
activity in hippocampal slices. We found that slices from animals given DBS had reduced
hippocampal excitability and were less susceptible to develop ictal activity. In live animals,
AN DBS significantly increased adenosine levels in the hippocampus as measured by
microdialysis. The reduced excitability of DBS in vitro was completely abolished in animals
pre-treated with A1 receptor antagonists and was strongly potentiated by A1 receptor
agonists. We conclude that some of the antiepileptic effects of DBS may be mediated by
adenosine.
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INTRODUCTION
Deep brain stimulation (DBS) involves the delivery of current
to the brain parenchyma though implanted electrodes. Over
the last decade, preclinical and clinical studies have shown that
DBS applied to the anterior thalamic nucleus (AN) reduces
seizure rate and increases the latency for the development
of seizures and status epilepticus (SE; Mirski et al., 1997;
Hodaie et al., 2002; Hamani et al., 2004, 2008; Kerrigan et al.,
2004; Andrade et al., 2006; Takebayashi et al., 2007a,b; Fisher
et al., 2010). Despite the efficacy of AN DBS, mechanisms
involved in the antiepileptic effects of this therapy remain
elusive.
We have recently shown that AN DBS reduced the frequency
of spontaneous recurrent seizures in chronic epileptic animals
(Covolan et al., 2014). In addition, animals receiving stimulation
had a significant decrease in hippocampal excitability. This proved
to be a more reliable measure of the effectiveness of DBS than
frequency of seizures, due to the variability in seizure rate that
occurs not only across animals but also in the same animals over
time (Covolan et al., 2014).
Adenosine and other purines are known modulators of neu-
ronal excitability and seizure activity in experimental animals
and humans (Dunwiddie, 1980; Turski et al., 1985; O’Brien,
1988; Arvin et al., 1989; During and Spencer, 1992; Boison
et al., 1999; Huber et al., 2001; Zuchora et al., 2001; Anschel
et al., 2004; Boison, 2005, 2006, 2008, 2009; Cunha, 2005;
Vianna et al., 2005; Pagonopoulou et al., 2006; Li et al., 2007,
2011; Boison and Stewart, 2009; Van Dycke et al., 2010, 2011;
Hargus et al., 2012). In rats, adenosine injections directly onto
the epileptic focus (Anschel et al., 2004) or the hippocam-
pus improve seizure control (Van Dycke et al., 2010). Syn-
thetic polymers capable of releasing adenosine into the ventricle
have also been shown to reduce seizure activity (Boison et al.,
1999). In preclinical models, SE up-regulates adenosine kinase
(ADK), a key metabolic enzyme for the regulation of extracel-
lular adenosine (Aronica et al., 2011). Fibroblasts engineered to
release adenosine by inactivating ADK and adenosine deaminase
grafted into the ventricles of kindled rats protected the ani-
mals from behavioral seizures and afterdischarges (Huber et al.,
2001).
In thalamic slices from ferrets, stimulation-induced glutamate
and adenosine release abolished spontaneous spindle oscillations
(Tawfik et al., 2010). In slices from mice, thalamic stimula-
tion increased ATP release and induced an accumulation in
extracellular adenosine (Bekar et al., 2008). In mice, A1 receptor
activation depressed excitatory transmission in vitro and reduced
both tremor- and DBS-induced side effects in vivo (Bekar et al.,
2008).
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Bearing in mind the fact that adenosine modulates seizures in
animal models and is involved in mechanisms of thalamic DBS for
tremor (Bekar et al., 2008), we hypothesized that this nucleoside
could be one of the substrates involved in the antiepileptic effects
of AN DBS.
RESULTS
AN-DBS INDUCES ADENOSINE RELEASE IN HIPPOCAMPUS
As shown in Figure 1, AN DBS increased hippocampal levels
of adenosine in both epileptic and non-epileptic animals (DBS
main effect F(1,12) = 527.59, p < 0.0001). This increase was
significantly higher in Pilo + DBS rats compared to Pilo + Sham
animals (Figure 1A). The same pattern was observed after 5 days
of stimulation (DBS main effect F(1,12) = 297.90, p < 0.0001;
Figure 1B), with the additional observation that mean adenosine
levels in the DBS + Pilo group were almost twice as high as their
own values on stimulation day 1 (p < 0.001). In both days 1
and 5, adenosine remained increased for at least 1 h following
DBS discontinuation. Levels of this nucleoside were significantly
higher in chronic epileptic animals as compared to non-epileptic
controls (Pilo main effect F(1,12) = 114.88, p < 0.001).
ANTIEPILEPTIC EFFECTS OF AN DBS IN VITRO
We have previously found that animals receiving DBS for 5 days
had a significant decrease in hippocampal excitability measured
in vitro with electrophysiology (Covolan et al., 2014). In preclin-
ical models, the antiepileptic effects of adenosine occur largely
through A1 receptors (Simonato et al., 1994; Ekonomou et al.,
1998; Gouder et al., 2003; Rebola et al., 2003; Avsar and Empson,
2004; Mohammad-Zadeh et al., 2005, 2009; Fedele et al., 2006;
Rosim et al., 2011; Silva et al., 2011). Based on these premises,
we hypothesized that the increased adenosine levels recorded
after DBS might be interacting with A1 receptors to reduce hip-
pocampal excitability. To test this hypothesis, we recorded activity
from slices of rats previously given 5 days of stimulation with or
without co-administration of the A1 antagonist 8-Cyclopentyl-
1,3-dipropylxanthine (DPCPX) or the A1 agonist R-isomer of
N6-phenylisopropyladenosine (R-Pia). In these experiments, we
did not record in vivo seizure rate due to the marked variability
observed across animals in our previous report (Covolan et al.,
2014).
Confirming our previous findings (Covolan et al., 2014),
epileptiform activity in slices of animals previously given AN
DBS had longer latencies (p = 0.04), with shorter (p < 0.01)
and smaller direct current (DC) shifts (p < 0.01), and a
smaller spike amplitude (p < 0.01), as compared to non-
stimulated epileptic controls (Figure 2). These effects were
completely abolished in animals given DPCPX (Figure 2).
In contrast, the protective effects of DBS were somewhat
potentiated in animals given DBS plus R-Pia. Slices from
this group had lower spike amplitudes (p < 0.01) and a
longer latency for the development of epileptiform events
(p < 0.01) as compared to those from rats receiving DBS
alone (Figure 2). No differences in activity have been
recorded in slices from animals given saline, DPCPX or R-Pia
alone.
DISCUSSION
Reduced hippocampal excitability and susceptibility for the devel-
opment of ictal activity after AN DBS in slices from chronic
FIGURE 1 | Anterior thalamic nucleus DBS effects on hippocampal
adenosine release. On the first day of stimulation (left panel), a
significant increase in adenosine release was measured soon after DBS
was started, persisting for almost 2 h after stimulation was
discontinued. On the fifth day of DBS (right panel) a similar trend was
seen but adenosine levels in Pilo + DBS animals were almost twice as
high as those recorded on stimulation day 1. Values are means and
SEM. N = 4 for all groups. *p < 0.012 (day 1) and p < 0.0062 (day 5)
Pilo + DBS compared to Pilo + Sham, Bonferroni-corrected tests. Other
significant comparisons are omitted for the sake of clarity.
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FIGURE 2 | Antiepileptic effects of AN DBS are mediated by A1
receptors. Chronic epileptic rats undergoing AN stimulation were
concomitantly given either the A1 receptor antagonist
8-cyclopentyl-1,3-dipropylxanthine (DPCPX) or the A1 agonist
R-N6-(2)-phenylisopropyladenosine (R-Pia). (A) In vitro recordings under a
zero calcium high potassium condition show epileptiform discharges
characterized by DC shifts intermingled with spiking activity. (B–E)
Box-and-whisker plots show that animals previously given DBS at 100 µA
had a longer latency for the development of epileptiform activity, shorter
and smaller DC shifts, and a smaller spike amplitude as compared to slices
from animals previously given no stimulation. The decrease in hippocampal
excitability observed after AN stimulation was almost completely reversed
in slices from animals previously given DBS + DPCPX. R-Pia potentiated
the antiepileptic effects of DBS. The box shows median, quartile 1 and 3.
The whiskers show minimal and maximal values. Significant differences
between the groups (p < 0.05; Kruskall Wallis followed by Mann Withney)
are represented as follows: DBS vs. sham *; DBS vs. DBS + DPCPX §; and
DBS vs. DBS + R-Pia ≈.
epileptic animals were completely blocked by treatment with
A1 antagonists and potentiated by the co-administration of
the A1 agonist R-Pia. This suggests that hippocampal adeno-
sine released after AN stimulation may activate A1 receptors
and subsequently lead to structural and/or functional changes
capable of rendering the hippocampus less susceptible to ictal
events.
The first interesting aspect of our study was the long-lasting
stimulation-induced release of adenosine. This nucleoside has
been shown to inhibit seizure activity both in vitro and in
animal models of epilepsy (Dunwiddie, 1980; Van Dycke et al.,
2010). We found that in chronic epileptic animals, the increase
in adenosine release after DBS not only outlasted the admin-
istration of current but was significantly more pronounced at
long-term. Bearing in mind the antiepileptic effects of adenosine,
one may speculate that the frequency of seizures and epilep-
tiform activity after AN stimulation could become less pro-
nounced with time. Though this has not been demonstrated
in animals, it has been reported in clinical trials (Fisher et al.,
2010). In a recent randomized controlled multicenter study,
the effects of AN DBS have been shown to build up with
time, being far more pronounced at long-term (Fisher et al.,
2010). Our results obviously do not allow us to conclude that
adenosine is involved in the increased efficacy of DBS over
time but they do suggest a path to be explored in future
studies.
Due to the high variability in seizure rate observed in the
pilocarpine model, we did not record the frequency of behavioral
or electrographic seizures in our dialysis experiments. That said,
animals selected for that part of the study were not those with
high number of seizures at baseline, as we were afraid of them
damaging the dialysis set up while having generalized ictal events
(this in fact did happen with one of our rats). A few animals in
the epileptic groups did have seizures that lasted a few seconds
during the experiments. As our samples were collected over
30 min, associated changes in levels of adenosine could not be
captured. Another interesting finding in our study was the fact
that epileptic animals had higher baseline levels of adenosine in
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the hippocampus compared to non-epileptic controls. Whether
this is a compensatory mechanism to hinder seizure activity
remains to be investigated. Finally, one may argue that the simple
implantation of electrodes in the brain might have contributed
to our results. We find this unlikely for two main reasons. First,
electrodes were implanted a few millimeters away from the collec-
tion site (AN vs. hippocampus). Second, no differences in baseline
adenosine levels have been recorded between DBS treated animals
and their respective controls (i.e., prior to stimulation onset).
We have focused on A1 receptors as these are highly expressed
in the hippocampus (Swanson et al., 1995) and have been
extensively demonstrated to be involved in the inhibition of
ictal activity (Fedele et al., 2006). Overall, our electrophysio-
logical experiments have shown that (1) the decrease in hip-
pocampal excitability observed after AN stimulation was almost
completely reversed in slices from animals previously given A1
antagonists; and (2) previous administration of A1 agonists
to animals receiving DBS potentiated the in vitro antiepilep-
tic effects of stimulation. Our results suggest that adenosine
released after DBS would activate A1 receptors and induce func-
tional and/or structural changes that might have decreased hip-
pocampal excitability and the propensity for seizures. In our
study, electrophysiology results in slices from animals receiving
R-Pia alone were not identical to those recorded in the DBS
group. This may be due to the fact that the effects of DBS
are fairly complex, involving synaptic and non-synaptic mech-
anisms as well as multiple neurotransmitter systems. A more
suggestive finding supporting the role of A1 receptors was the
reduced hippocampal excitability recorded in animals previously
given DBS was completely abolished by the co-administration of
DPCPX.
As a final remark we would like to point out two caveats of
our study. First, we have only recorded electrophysiological data 5
days after DBS onset, an interval that was based on our previous
report (Covolan et al., 2014). In contrast, our dialysis experiments
were conducted at two time points. As in our previous studies
DBS was shown to induce an increase in neurotransmitter release
right after stimulation onset (Hamani et al., 2010), we have
decided to record adenosine levels within the first hours of DBS
administration. To understand whether changes in adenosine
levels after stimulation were sustained and still noticeable within
the timeframe of our electrophysiological recordings, we have also
conducted dialysis experiments after 5 days of DBS. At present,
it is still unclear whether the administration of A1 antagonists
blocks the effects of 1-day DBS treatment. As a second remark,
we did not record behavioral seizure rate, dialysis samples and
in vitro electrophysiology in the same animals for the reasons
described above. As a result, we could not correlate these events
and are unable to provide a clear causal relationship between
hippocampal excitability, adenosine levels and the frequency of
behavioral seizures.
In summary, we found that the purinergic system may be
involved in the antiepileptic effects of AN DBS. In the clinical
scenario, 40–60% of patients with treatment refractory epilepsy
are responsive to AN DBS (Fisher et al., 2010). Therapeutic strate-
gies for individuals considered as being non-responders remain
unclear. Though no pure A1 agonist is available for clinical use,
our findings may pave the way for future investigation on the use
of medications that influence A1 receptors to potentiate the effects
of stimulation.
MATERIALS AND METHODS
Protocols were approved by the Animal Care committee of the
Universidade Federal de São Paulo (CEUA 1482/11).
SURGERY AND AN STIMULATION
Four months after pilocarpine injections (Pilo; 320 mg/Kg i.p.),
adult male Wistar rats (250–300 g) were divided in groups to
receive DBS or sham-surgery (holes drilled in the skull). Animals
with implanted electrodes that did not receive stimulation have
not been included as such treatment did not lead to significant dif-
ferences as compared to non-implanted controls in our previous
work (Covolan et al., 2014). Under ketamine/xylazine anesthesia
(100/7.5 mg/kg i.p.), animals in the DBS group had insulated
stainless steel electrodes (cathodes; 250 µm diameter; 0.5 mm
exposed length) bilaterally implanted into the AN (anteroposte-
rior −1.5 mm, lateral ±1.5 mm, depth 5.2 mm) (Paxinos and
Watson, 1998). A screw implanted over the right somatosensory
cortex was used as the anode. On the second postoperative week,
DBS was administered for 5 days (8 h/day) using a portable
stimulator (St Jude Medical, Plano, TX) at 130 Hz, 90 µs, and
100 µA. These settings were chosen as they were effective against
pilocarpine-induced chronic epileptic seizures in our previous
study (Covolan et al., 2014).
ELECTROPHYSIOLOGY
Prior to the experiments, chronic epileptic rats were given 5
days of DBS with or without the concomitant administration
of the A1 receptor antagonist DPCPX (50 µg/kg/day i.p.) or
agonist R-Pia (25 µg/kg/day i.p.) (Vianna et al., 2005). Following
CO2 narcosis, animals were decapitated, brains were removed
and 400 µm hippocampal slices were cut on a vibratome. Slices
were then individually transferred to an interface-type chamber,
placed on a membrane (0.4 µm Millicell culture plate inserts;
Millipore, Badford, MA) and continuously bathed with artificial
cerebrospinal fluid (aCSF; 127 mM NaCl, 2 mM KCl, 1.5 mM
MgSO4, 1.1 mM KH2PO4, 26 mM NaHCO3, 2 mM CaCl2, and
10 mM glucose) at 33◦C under a stream of moisturized 95% O2—
5% CO2. Slices were left undisturbed for 40 min before being
perfused with a zero calcium and 8 mM potassium solution for
approximately 1 h and 30 min (de Almeida et al., 2008).
Extracellular field potentials were recorded from the hip-
pocampal dentate gyrus (DG), as previously described (de
Almeida et al., 2008). For each group, slices containing the dorsal
hippocampus of six different animals were analyzed (14 extra-
cellular potentials per animal). The following parameters were
studied: latency for epileptiform discharges after perfusion with
a zero calcium high potassium solution; DC shift; amplitude of
population spikes; and event duration. A digital Fourier trans-
form was used to quantify DC shifts. Once in the frequency
domain, the event signal was recalculated taking into account
only components below 10 Hz. This process allowed the analysis
of DC shifts without interference from population spikes. Event
duration was calculated by subtracting the final time from the
initial time of an event (de Almeida et al., 2008).
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MICRODIALYSIS
Along with the implantation of DBS electrodes, a microdialysis
cannula was placed into the right dorsal hippocampus (antero-
posterior −3.7 mm, lateral 2.4 mm, depth 5.1 mm) (Paxinos and
Watson, 1998). Five days later, a microdialysis probe (CMA/12-
2 mm, CMA Microdialysis, Sweden) was inserted into the target
and perfused with a Ringer’s solution at 1 µL/min (Macedo et al.,
2012). Dialysate samples were collected every 30 min in vials
containing 0.25 mM ascorbic acid, Na2EDTA 0.27 mM, 0.1 M
acetic acid on the first and last days of treatment at baseline (2 h),
during DBS (3 h), and in the 3 h following stimulation offset
(n = 4 animals per group).
Adenosine levels were detected with capillary electrophore-
sis (Beckman-Coulter PACE/MDQ, Beckman Coulter, USA)
equipped with a laser-induced fluorescence detector (ZETALIF
Picometrics, France; He-Cd laser wavelength 410 nm). Dialysate
samples (20 µl) were derivatizated with 20 µl of a chloroacetalde-
hyde solution (0.15 M) (Sigma, USA). This mixture was allowed
to react at 100◦C for 20 min, subsequently refrigerated at 4◦C
and then injected into the capillary system. Adenosine analysis
was carried out using a 20 mM sodium-phosphate buffer (con-
taining 1% SDS, pH 8). The applied voltage was 20 kV. Samples
were hydrodynamically injected (0.4 nl) in a fused-silica capillary
(Beckman-Coulter, 25 µm i.d. and 375 µm o.d., 60 cm in length,
and an effective length of 40 cm). The capillary was sequentially
flushed with sodium hydroxide (0.1 M), ultra-pure water, and
running buffer between each analysis. Electropherograms were
acquired at 15 Hz using a PACE MDQ software (Beckman-
Coulter).
STATISTICAL ANALYSES AND HISTOLOGY
Dialysis results for baseline, DBS and post-DBS periods were each
analyzed with a mixed model ANOVA, with pilocarpine and DBS
as between-subject factors and time as a within-subjects factor. As
electrophysiological data was non-parametric, results were com-
pared using the Kruskall Wallis and Mann Whitney tests. Dialysis
data is displayed as mean ± standard error. Electrophysiology
results are shown as median ± quartiles. Statistical significance
was considered when p ≤ 0.05.
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